Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Inclusion Criteria:

• Insulin naïve subject (allowed are: previous short term insulin treatment up to 14days; Treatment during hospitalisation or during gestational diabetes is allowed forperiods longer than 14 days)

• Current treatment: metformin monotherapy or metformin in any combination with aninsulin secretagogue (sulfonylurea or glinide), DPP-4 inhibitor,alpha-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 monthsprior to visit 1 with the minimum doses stated: -Metformin: alone or in combination (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000mg daily) -Insulin secretagogue (sulfonylurea or glinide): minimum half of the dailymaximal dose according to local labelling -DPP-4 inhibitor: minimum half of the dailymaximal dose according to local labelling - alpha-glucosidase-inhibitors (acarbose):minimum half of the daily maximal dose or maximum tolerated dose

• HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

• Body Mass Index (BMI) maximum 45.0 kg/m^2

• Type 2 diabetes (diagnosed clinically) for at least 6 months

• Ability and willingness to adhere to the protocol including performance of selfmonitored plasma glucose (SMPG) profiles according to the protocol

Exclusion Criteria:

• Use within the last 3 months prior to Visit 1 of: thiazoledinediones (TZDs), exenatideor liraglutide

• Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke;decompensated heart failure New York Heart Association (NYHA) class III or IV;myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft orangioplasty

• Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

• Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequatecontraceptive measures according to local requirements [for UK: adequate contraceptivemeasures are defined as established use of oral, injected or implanted hormonalmethods of contraception, sterilisation, intrauterine device or intrauterine system,or consistent use of barrier methods]

• Cancer and medical history of cancer hereof (except basal cell skin cancer or squamouscell skin cancer)